**УРОВНИ МЕСТНЫХ ЦИТОКИНОВ КАК ПРОГНОСТИЧЕСКИЙ ФАКТОР РАННЕГО РЕЦИДИВА НЕМЫШЕЧНО-ИНВАЗИВНОЙ КАРЦИНОМЫ МОЧЕВОГО ПУЗЫРЯ**

Златник Е. Ю. 1,

Сагакянц А. Б. 1,

Шульгина О. Г. 1,

ШевченкоА. Н. 1,

ФилатоваЕ. В. 1,

Белякова Л. И. 2,

БреусА. А. 1,

Маслов А. А. 1,

Маслов А. А. 3,

Розенко Л. Я. 1

1 ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Россия

2 ЦАОП ГБУ РО «КДЦ «Здоровье», г. Ростов-на-Дону

3 ФГБОУ ВО Ростовский Государственный медицинский Университет Минздрава России, г. Ростов-на-Дону

**LOCAL CYTOKINES` LEVELS AS PROGNOSTIC FACTORS FOR EARLY RELAPSE OF NON-MUSCLE-INVASIVE BLADDER CARCINOMA**

Zlatnik E. Yu. a,

Sagakyants A. B. a,

Shulgina O. G. a,

Shevchenko A.N. a,

Filatova E. V. a,

Belyakova L. I. b,

Breus A. A. a,

Maslov A. A. a,

Maslov A. A. c,

Rozenko L. Y. a

a National Medical Research Centre for Oncology, Rostov-on-Don, Russia

b Clinical and Diagnostic Center «Zdorovie» Rostov-on-Don, Russia

c RSMU Rostov State Medical University, Rostov-on-Don, Russia

**Резюме.**

Цель работы: дать оценку локального уровня цитокинов в качестве возможных прогностических факторов раннего рецидивирования немышечно-инвазивного мочевого пузыря (НМИРМП). В исследование включено 75 больных: 51 с первичным и 24 – с рецидивным НМИРМП; в обеих группах были опухоли высокой и низкой степени злокачественности (HG и LG). Больных с первичным НМИРМП наблюдали в течение 9 мес. после лечения: ТУР и адъювантная химиотерапия (№6). Из образцов опухолевой ткани готовили супернатанты, в которых определяли уровни цитокинов (IL-1β, IL-6, IL-10, IL-18, TNF-α, INF-γ, IL-8) методом ИФА. Результаты исследования показали, что у больных с первичным НМИРМП рецидивы развились в 15 случаях (46,8%) LG и в 11 (45%) – HG опухолей; не выявлено различий в зависимости от степени злокачественности. В исходно рецидивных опухолях как HG, так и LG, уровни цитокинов были максимальными: в LG они превышали первичные от 7,1 (INF-γ) до 300 (IL-6) раз, в HG - от 2,0 (IL-10) до 9,7 (IL-6) раз. Уровни IL-1β, IL-6, IL-10, INF-γ, IL-8 были выше в тех первичных LG опухолях, которые рецидивировали через 6-9 мес. наблюдения, чем в нерецидивировавших, хотя их содержание было значительно ниже, чем в исходно рецидивных опухолях (от 2,6 раз для INF-γ до 150 раз для IL-6). Сходная тенденция, хотя и не по тем же цитокинам, наблюдалась в HG опухолях: тканевые уровни IL-6, IL-10, IL-18 и TNF-α были выше в опухолях, рецидивировавших через 6-9 мес. после лечения. Повышение уровней двух цитокинов было общим для LG и HG опухолей (IL-6 и IL-10), что можно рассматривать в качестве нового фактора негативного прогноза. Таким образом, рецидивирование LG и HG НМИРМП связано с некоторыми иммунологическими механизмами, а именно, с локальной гиперпродукцией цитокинов, особенно IL-6 и IL-10, хотя IL-1β, IL-8, INF-γ могут играть роль при LG, а IL-18, TNF-α - при HG опухолях. Учитывая общие сигнальные пути IL-6 и IL-10 (JAK/STAT), эти транскрипционные факторы могут быть потенциальными мишенями для новых эффективных подходов к лечению.

**Ключевые слова:** цитокины, микроокружение опухоли, прогноз, немышечно-инвазивный рак мочевого пузыря, раннее рецидивирование

**Abstract.**

The aim of our study is to assess the local cytokines` levels as prognostic factors for early relapse in NMIBC patients. 75 patients with NMIBC were enrolled in the study: 51 with primary NMIBC and 24 with initially recurrent NMIBC, LG and HG tumors were diagnosed in each group. Patients with primary NMIBC were monitored during 9 months after treatment: TURB and chemotherapy (№6). During TURB samples of tumors were taken, supernatants were obtained and tissue cytokines` levels were measured (IL-1β, IL-6, IL-10, IL-18, TNF-α, INF-γ, IL-8) by ELISA test. The results showed that in patients with primary NMIBC early relapses were diagnosed in 15 (46,8%) of LG tumors and in 11 (45%) of HG tumors matching that there was no difference depending upon tumor grade. In initially recurrent tumors of both LG and HG NMIBC the amounts of cytokines were maximal: in LG tumors they exceeded the primary ones from 7,1 (INF-γ) to 300 (IL-6) while in HG - from 2,0 (IL-10) to 9,7 (IL-6). The amounts of IL-1β, IL-6, IL-10, INF-γ, IL-8 were higher in those LG primary tumors which relapsed in 6-9 months compared to the ones which didn`t, though their levels were much lower than in initially manifested relapse (from 2,6 times for INF-γ to 150 times for IL-6). Similar trend, though not for all the same cytokines, was observed in HG tumors: tissue levels of IL-6, IL-10, IL-18 and TNF-α were higher in tumors which relapsed in 6-9 months after treatment. The increase of 2 cytokines` levels were common for both LG and HG tumors (IL-6 and IL-10). This finding might be considered as a new prognostic factor of the early relapse. We conclude that relapse of LG and HG NMIBC is related to some immune mechanisms, namely to local hyperproduction of cytokines, especially IL-6 and IL-10, though IL-1β, IL-8, INF-γ could have an impact on LG and IL-18, TNF-α - on HG tumors. Taking into account common signalling pathways of IL-6 and IL-10 like JAK/STAT, these transcription factors might be potential targets for new effective approaches to treatment.

**Key words:** cytokines, tumor microenvironment, prognosis, non-muscle-invasive bladder carcinoma, early relapse

**Introduction.**

Chronic inflammation is considered to be one of the main triggers of carcinogenesis in many types of malignant tumors. Local hyperproduction of cytokines by tumor cells or activated macrophages and lymphocytes contributes to tumor microenvironment (TME) formation which plays a crucial role in immunoediting of tumor growth [3,6,12]. It is well known that cytokines are able to enhance neoangiogenesis and epithelial-mesenchymal transition (EMT), and disrupt the extracellular matrix, as well as to cause the migration to TME of immunosuppressive cells like M2, Tregs or MDSC [13]. Inflammatory cytokines can cause epigenetic modifications that upregulate the expression of oncogenes or downregulate the expression of tumor-suppressor genes [5]. IL-10, IL-6, TGF-β are described by many researchers as prooncogenic, nevertheless cytokines, proclaimed as immunostimulating (IL-1β, TNF-α, IFN-α and γ and some others) seem to possess dual function in tumor-bearing organism and demonstrate promotion not only of immune response but also of tumor growth [8].

Relapse of malignant tumors following months or even years after treatment including surgery and radio- and/or chemotherapy is usually considered to be a problem of insufficiently radical approach. But nowadays more and more data proves the biologic causes of tumor recurrence, emphasizing the role of cancer stem cells [9] and cytokines of TME [7,10]. At the time of the first referring for medical care 75-80% of patients with urothelial bladder carcinoma have non-muscle-invasive tumor (NMIBC), i.e. located in mucosa (Та, CIS), or submucosa (st. Т1). Though it is the initial stage of bladder cancer, the tumor has a marked tendency to recur even when the treatment is started timely. According to European Organization for the Research and Treatment of Cancer (EORTC) the most often type of tumor progression in NMIBC is relapse occurring in 37% of patients with low risk, in 65% of patients with intermediate risk and in 84% of patients with high risk after transurethral bladder resection (TURB) and adjuvant chemotherapy. In the last case early relapses are typically diagnosed during 6-12 months after surgery and chemotherapy, especially in high grade (HG) carcinomas; such patients need more aggressive treatment. That is why the search for new prognostic factors which might also serve as targets for treatment of NMIBC is an topical medical and biological problem.

The aim of our study is to assess the local cytokines` levels as prognostic factors for early relapse in NMIBC patients.

Materials and methods. 75 patients with NMIBC were treated in the Department of Urology of National Medical Research Centre for Oncology, Rostov-on-Don, Russia. The group of 51 patients (46 men (90,2%) and 5 women (9,8%) aged 40-83 years) had primary NMIBC which was histologically verified as papillary urothelial carcinoma: low grade (LG, n=31 or 60,8%) and high grade (HG, n=20 or 39,2%). All the patients were in high and intermediate risk groups according to EORTC; they received surgical treatment (TURB) and 6 courses of adjuvant intravesical chemotherapy. Patients were monitored during 9 months after treatment. Patients of the group with initially recurrent NMIBC (n=24), had LG tumors (n=15 or 62,5%) and HG tumors (n=9 or 37,5%). They were also subjected to surgical treatment and chemotherapy according to the accepted standards. Prior to enrollment in the study, all participants gave written informed consent.

The samples of tumors were taken from all the patients during TURB, disintegrated by BD Medimachine (USA), supernatants were obtained by centrifugation and stored at -80oC. After thawing sandwich Elisa test was performed with cytokine kits to estimate the levels of IL-1β, IL-6, IL-10, IL-18, TNF-α, INF-γ, IL-8 (Vector-Best, Russia) by Uniplan Reader (Russia). Total protein amount was measured by biuret test on analyzer Sinnowa Medical Science and Technology Co (China). Cytokines` levels were expressed in pg/ml per 1 g protein. Statistical analysis was performed by program STATISTICA 13 (StatSoftInc., USА). Since our data had no Gaussian (normal) distribution they were represented as median with interquartile range – 25 and 75 percentiles (Ме [LQ; UQ]). Intergroup differences were estimated by Mann-Whitney U-test. Statistically significant differences were accounted when p<0,05.

Results and discussion. During the period of clinical monitoring of the patients with primary NMIBC early relapses were diagnosed in 15 (46,8%) of them with LG tumors and in 11 (45%) with HG tumors matching that there was no difference depending upon tumor grade. Patients without these early relapses were regarded as groups 1 in LG and 4 in HG (better prognosis) and with newly diagnosed early relapses as groups 2 in LG and 5 in HG (worse prognosis) while patients with initially recurrent tumors formed groups 3 in LG and 6 in HG.

Comparative analysis of tissue cytokine contents between these groups with different course of the disease is shown in table 1. In relapse tumors (groups 3 and 6) of both LG and HG NMIBC the amounts of most of cytokines were maximal: in LG tumors they exceeded the primary ones from 7,1 (INF-γ) to 300 (IL-6) while in HG - from 2,0 (IL-10) to 9,7 (IL-6). It is worth noting that in HG tumors some cytokines demonstrated no difference between the recurrent and the primary ones (INF-γ) and IL-18 level was higher in relapse HG tumors than in primary ones of the group 4, but not 5. We found out that primary tumors which manifested relapse after 6-9 months after treatment also contained higher cytokines` levels than primary tumors without relapse during this period and it was typical for both groups. The amounts of IL-1β, IL-6, IL-10, INF-γ, IL-8 were statistically significantly higher in those LG primary tumors which relapsed in 6-9 months compared to the ones which didn`t, though their levels were much lower than in initially manifested relapse (2,6 times for INF-γ and 150 times for IL-6). Similar trend, though not for all the same cytokines, was observed in HG tumors: tissue levels of IL-6, IL-10, IL-18 and TNF-α were statistically significantly higher in tumors which relapsed in 6-9 months after treatment. This finding might be considered a new prognostic factor of the early relapse. Based on the values of the ranged data represented as LQ and UQ we tried to specify the limits of cytokines` indicators possibly prognostic for early relapse during the period of monitoring. For LG tumors the value appeared to be IL-1β>18,0, IL-6>1,5, IL-10>4,2, INF-γ>8,4, IL-8>15,3 pg/ml per 1 g of protein and for HG tumors IL-6>3,9, IL-10>3,9, IL-18>34,4, TNF-α>7,2 pg/ml per 1 g of protein. We observed that the increase of 2 cytokines` levels were common for both LG and HG tumors (IL-6 and IL-10). So they might be used as a possible prognostic factors for early relapse in patients with NMIBC though verification on more broad groups and more prolonged monitoring is needed.

Accounting the biologic properties of both cytokines, it is rather expected. IL-6 induces invasion and metastasis through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway and thus is able to activate a wide array of signalling pathways and transcription factors promoting EMT, fostering the acquisition of mesenchymal features in cancer cells [1]. The other type of its` prooncogenic activity is support of cancer stem cells which are considered to be a pool for relapse forming from treatment-resistant tumor cells [11]. IL-10 is known to be an immunosuppressive factor of TME due to suppression of T cell proliferation, modulation of APCs, preservation of the activity/stability of Treg cells, though it remains unclear if it can stimulate them [4]. Notably, both IL-6 and IL-10 are involved in STAT3 activation matching that pro-inflammatory and anti-inflammatory cytokines can work through the same signaling pathway, although they perform very distinct functions and their downstream mechanisms are different. In the review cited above the authors point out that in macrophages, both IL-10 and IL-6 induce the activation of SOCS3, and this could be the target for future therapeutic approaches.

From our previous experience high levels of IL-6 and IL-10 in TME were factors of poor prognosis in patients with melanoma and esophageal carcinoma [2, 14,15]

Conclusions. We consider that relapse of LG and HG NMIBC is related to some immune mechanisms, namely to local hyperproduction of cytokines, especially IL-6 and IL-10, though IL-1β, IL-8, INF-γ could have an impact on LG and IL-18, TNF-α - on HG tumors. Taking into account common signalling pathways of IL-6 and IL-10 like JAK/STAT, these transcription factors might be potential targets for new effective approaches to treatment.

**TABLES**

**Table 1.** Tissue cytokines` levels in tumors of NMIBC patients with different course of the disease (Me; LQ, UQ)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cytokine level (pg/ml per 1 g of protein) | Groups of patients | | | | | | | |
| NMIBC LG | | | | NMIBC HG | | | |
| 1  Primary without relapse,  n=16 | 2  Primary with relapse in 6-9 months,  n=15 | 3  Relapse,  n=15 | р | 4  Primary without relapse,  n=11 | 5  Primary with relapse in 6-9 months,  n=9 | 6  Relapse,  n=9 | p |
| IL-1β | 13,3  (10,2;17,9) | 19,8**1**  (19,1;48,9) | 149,2**1,2**  (83;215,4) | p(2-1)=0,038  p(3-1)=0,001  p(3-2)=0,001 | 31,3**1**  (17,3;41) | 38,5**2**  (26,7;49,6) | 83,8**3,4,5**  (60,8;91,1) | p(6-4)=0,035  p(6-5)=0,04 |
| IL-6 | 1,1  (0,6;1,5) | 2,6**1**  (2,2;7,3) | 330,2**1,2**  (167,8;492,6) | p(2-1)=0,025  p(3-1)=0,001  p(3-2)=0,001 | 3,0**1**  (1,3;3,9) | 6,2**2,4**  (4,5;9,2) | 29,2**3,4,5**  (29,1;31,7) | p(5-4)=0,027  p(6-4)=0,011  p(6-5)=0,008 |
| IL-10 | 3,2  (2,1;4,2) | 5,9**1**  (4,9;9,9) | 55,4**1,2**  (29,4;81,4) | p(2-1)=0,039  p(3-1)=0,012  p(3-2)=0,019 | 3,6  (1,6;3,9) | 5,1**4**  (4,2;5,6) | 7,2**3,4,5**  (6,1;10,5) | p(5-4)=0,04  p(6-4)=0,039  p(6-5)=0,037 |
| IL-18 | 59,7  (41,8;90) | 57,3  (31,7;81,5) | 641,0**1,2**  (478,2;903,9) | p(3-1)=0,014  p(3-2)=0,016 | 22,8**1**  (20,3;34,4) | 87,6**2,4**  (83,9;124,1) | 69,0**3,4,5**  (46,9;80,4) | p(5-4)=0,012  p(6-4)=0,001  p(6-5)=0,035 |
| TNFα | 10,1  (5,9;13,8) | 10,0  (7,1;17,5) | 212,0**1,2**  (113,3;310,7) | p(3-1)=0,001  p(3-2)=0,001 | 5,5**1**  (4,5;7,2) | 10,9**4**  (8,3;12,7) | 22,7**3,4,5**  (21,9;42,7) | p(5-4)=0,032  p(6-4)=0,018  p(6-5)=0,012 |
| INF-ɣ | 6,9  (4,9;8,4) | 19,0**1**  (11,1;38,9) | 49,0**1,2**  (28,9;69,2) | p(2-1)=0,021  p(3-1)=0,017  p(3-2)=0,039 | 15,2**1**  (11;20,9) | 11,2  (5,3;19,4) | 10,8**3**  (9,8;16,1) |  |
| IL-8 | 13,0  (8,4;15,3) | 26,4**1**  (22,4;37,8) | 663,4**1,2**  (341,6;985,2) | p(2-1)=0,028  p(3-1)=0,001  p(3-2)=0,001 | 69,4**1**  (47,5;113,2) | 42,6**2,4**  (38,4,4;45,7) | 190,9**3,4,5**  (125,7;329,2) | p(5-4)=0,043  p(6-4)=0,014  p(6-5)=0,022 |

**ТИТУЛЬНЫЙ ЛИСТ\_МЕТАДАННЫЕ**

**Блок 1. Информация об авторе ответственном за переписку**

**Златник Елена Юрьевна**, д.м.н., профессор, главный научный сотрудник лаборатории Иммунофенотипирования опухолей ФГБУ «НМИЦ онкологии» Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

Тел: 8-961-272-69-68

E-mail: elena-zlatnik@mail.ru

Zlatnik Elena Yurievna, Doct.Med.Sc., Professor, chief researcher of Laboratory of immunophenotyping of tumors National Medical Research Centre for Oncology

344019, Rostov-on-Don, 14 Liniya, 63

Phone: 8-961-272-69-68

E-mail: elena-zlatnik@mail.ru

**Блок 2. Информация об авторах**

**Сагакянц Александр Борисович,** к.б.н., доцент, заведующий лабораторией иммунофенотипирования опухолей, ФГБУ "НМИЦ онкологии" Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

**Sagakyants Alexander Borisovich**, Associate Professor, PhD, Head of Laboratory of immunophenotyping of tumors at National Medical Research Centre for Oncology; 344019, Rostov-on-Don, 14 Liniya, 63; E-mail: asagak@rambler.ru

**Шульгина Оксана Геннадьевна**, м.н.с. лаборатории Иммунофенотипирования опухолей ФГБУ «НМИЦ онкологии» Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

**Shulgina Oksana Gennadievna,** junior researcher of Laboratory of immunophenotyping of tumors at National Medical Research Centre for Oncology; 344019, Rostov-on-Don, 14 Liniya, 63; E-mail: iftrnioi@yandex.ru

**Шевченко Алексей Николаевич**, д.м.н., профессор, заведующий отделением онкоурологии ФГБУ «НМИЦ онкологии» Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

**Shevchenko Aleksej Nikolaevich**, Dr. Med. Sci, professor, head of oncourological department at National Medical Research Centre for Oncology; 344019, Rostov-on-Don, 14 Liniya, 63

**Филатова Елена Валерьевна,** к.м.н., врач-онколог, научный сотрудник, ФГБУ «НМИЦ онкологии» Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

**Filatova Elena Valer`evna,** Cand. Med. Sci. at National Medical Research Centre for Oncology; 344019, Rostov-on-Don, 14 Liniya, 63

**Белякова Любовь Игоревна**, врач-онколог ЦАОП ГБУ РО «КДЦ «Здоровье» в г. Ростов-на-Дону

**Belyakova Lubov Igorevna**, oncologist Clinical and Diagnostic Center «Zdorovie» Rostov-on-Don; E-mail: drlbelyakova@yandex.ru

**Бреус Анна Александровна,** к.м.н., врач-онколог ФГБУ «НМИЦ онкологии» Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

**Breus Anna Aleksandrovna**, Cand. Med. Sci. at National Medical Research Centre for Oncology; 344019, Rostov-on-Don, 14 Liniya, 63

**Маслов Андрей Александрович,** д.м.н., профессор, главный врач, руководитель отделения абдоминальной онкологии № 3 ФГБУ «НМИЦ онкологии» Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

**Maslov Andrey** **Aleksandrovich,** Dr. Med. Sci, professor, Chief Physician, Head of Abdominal Oncology Department No. 3 at National Medical Research Centre for Oncology; 344019, Rostov-on-Don, 14 Liniya, 63

**Маслов Александр Андреевич,** студент ФГБОУ ВО РостГМУ Минздрава России, Россия, 344022, Ростов-на-Дону, пер. Нахичеванский, 29

**Maslov Alexander Andreevich,** student at RSMU Rostov State Medical University, Rostov-on-Don, Russia, Nahichevansky av., 29

**Розенко Людмила Яковлевна,** д.м.н., профессор, врач-онколог, ФГБУ «НМИЦ онкологии» Минздрава России, 344019, Ростов-на-Дону, 14-я Линия, 63

**Rozenko Lyudmila YAkovlevna** Dr. Med. Sci, professor, oncologist at National Medical Research Centre for Oncology; 344019, Rostov-on-Don, 14 Liniya, 63

**Блок 3. Метаданные статьи**

**УРОВНИ МЕСТНЫХ ЦИТОКИНОВ КАК ПРОГНОСТИЧЕСКИЙ ФАКТОР РАННЕГО РЕЦИДИВА НЕМЫШЕЧНО-ИНВАЗИВНОЙ КАРЦИНОМЫ МОЧЕВОГО ПУЗЫРЯ**

**LOCAL CYTOKINES` LEVELS AS PROGNOSTIC FACTORS FOR EARLY RELAPSE OF NON-MUSCLE-INVASIVE BLADDER CARCINOMA**

**Сокращенное название статьи для верхнего колонтитула:**

ЦИТОКИНЫ И ПРОГНОЗ РЕЦИДИВА НМИРМП

CYTOKINES PREDICT RELAPSE OF NMIBC

**Ключевые слова:** цитокины, микроокружение опухоли, прогноз, немышечно-инвазивный рак мочевого пузыря, раннее рецидивирование

**Key words:** cytokines, tumor microenvironment, prognosis, non-muscle-invasive bladder carcinoma, early relapse

Материалы Форума "ДНИ ИММУНОЛОГИИ В САНКТ-ПЕТЕРБУРГЕ 2023"

Количество страниц текста – 3

Количество таблиц – 1

Количество рисунков – 0

Дата поступления 11.04.2023

**СПИСОК ЛИТЕРАТУРЫ**

|  |  |  |  |
| --- | --- | --- | --- |
| № | Авторы, название публикации, источник | Англоязычное название | URL |
| 1 | Abaurrea A., Araujo A.M., Caffarel M.M. The Role of the IL-6 cytokine family in epithelial-mesenchymal plasticity in cancer progression. Int J Mol Sci, 2021, Vol. 22, no.15, pp. 8334. doi: 10.3390/ijms22158334 | - | <https://www.mdpi.com/1422-0067/22/15/8334> |
| 2 | Bazaev A.L., Kit O.I., Zlatnik E.Y., Kolesnikov E.N., Trifanov V.S., Snezhko A.V., Myagkov R.E., Averkin M.A., Selyutina O.N., Bondarenko E.S., Zolotareva E.I., Kazieva T.B., Sanamyants S.V. Factors of local immunity in esophageal tumors of various stages. J Clin Oncol, 2018, 36(15\_suppl), e16013. doi: 10.1200/JCO.2018.36.15\_suppl.e16013 | - | <https://www.researchgate.net/publication/327452874_Factors_of_local_immunity_in_esophageal_tumors_of_various_stages> |
| 3 | Cao R., Yuan L., Ma B., Wang G., Tian Y. Tumor microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol Immunother, 2021, Vol. 70, no.1, pp. 1-18. doi: 10.1007/s00262-020-02649-x | - | <https://link.springer.com/article/10.1007/s00262-020-02649-x> |
| 4 | Chang C.M., Lam H.Y.P., Hsu H.J., Jiang S.J. Interleukin-10: A double-edged sword in breast cancer. Tzu Chi Med J, 2021, Vol. 33, no.3, pp. 203-211. doi: 10.4103/tcmj.tcmj\_162\_20 | - | <https://journals.lww.com/tcmj/Fulltext/2021/33030/Interleukin_10__A_double_edged_sword_in_breast.1.aspx> |
| 5 | Grivennikov S.I. Inflammation and colorectal cancer: Colitis-associated neoplasia. Semin. Immunopathol, 2013, Vol. 35, pp. 229–244. doi: 10.1007/s00281-012-0352-6 | - | <https://link.springer.com/article/10.1007/s00281-012-0352-6> |
| 6 | Hatogai K., Sweis R.F. The tumor microenvironment of bladder cancer. Adv Exp Med Biol, 2020, Vol. 1296, pp. 275-290. doi: 10.1007/978-3-030-59038-3\_17 | - | <https://link.springer.com/chapter/10.1007/978-3-030-59038-3_17> |
| 7 | Kartikasari A.E.R.,  Huertas C.S.,  Mitchell A., Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis, Front Oncol, 2021, Vol. 11, pp. 692142 doi: 10.3389/fonc.2021.692142 | - | <https://www.frontiersin.org/articles/10.3389/fonc.2021.692142/full> |
| 8 | Lan T., Chen L., Wei X. Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy. Cells, 2021, Vol. 10, no.1, pp. 100. doi: 10.3390/cells10010100 | - | <https://www.mdpi.com/2073-4409/10/1/100> |
| 9 | Marzagalli M., Fontana F., Raimondi M., Limonta P. Cancer stem cells-key players in tumor relapse. Cancers (Basel), 2021, Vol. 13, no.3, pp. 376. doi: 10.3390/cancers13030376 | - | <https://www.mdpi.com/2072-6694/13/3/376> |
| 10 | Morris R.M., Mortimer T.O., O'Neill K.L. Cytokines: can cancer get the message? Cancers (Basel), 2022, Vol. 14, no.9, pp. 2178. doi: 10.3390/cancers14092178 | - | <https://www.mdpi.com/2072-6694/14/9/2178> |
| 11 | Radharani N.N.V., Yadav A.S., Nimma R., Kumar T.V.S. , Bulbule A., Chanukuppa V., Kumar D., Patnaik S., Rapole S., Kundu G.C. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int, 2022, Vol. 22, no. 1, pp. 122. doi: 10.1186/s12935-022-02527-9 | - | <https://cancerci.biomedcentral.com/articles/10.1186/s12935-022-02527-9> |
| 12 | Сагакянц А.Б., Белякова Л.И., Шевченко А.Н., Бондаренко Е.С., Златник Е.Ю., Новикова И.А., Филатова Е.В., Хван В.К., Хомутенко И.А., Бурцев Д.В. Особенности локального иммунитета у пациентов с неинвазивно-мышечным раком мочевого пузыря различной степени злокачественности // Южно-Российский онкологический журнал. – 2022. – Т.3. -№4. - С.58-66. doi: 10.37748/2686-9039-2022-3-4-6 | Sagakyants A.B., Belyakova L.I., Shevchenko A.N., Bondarenko E.S., Zlatnik E.Yu., Novikova I.A., Filatova E.V., Hvan V.K., Khomutenko I.A., Burtsev D.V. Local immunity features in patients with non-invasive muscular bladder cancer of various degrees of malignance. South Russian Journal of Cancer, 2022, Vol.3, no.4, pp. 58-66. doi: 10.37748/2686-9039-2022-3-4-6 | <https://www.cancersp.com/jour/article/view/198> |
| 13 | Suarez-Carmona M., Lesage J., Cataldo D., Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol, 2017, Vol. 11, no.7, pp. 805-823. doi: 10.1002/1878-0261.12095 | - | <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496491/> |
| 14 | Златник Е.Ю., Базаев А.Л., Кочуев С.С. Прогностическая значимость тканевого уровня цитокинов при некоторых злокачественных опухолях // Российский иммунологический журнал. - 2019. - Т. 22. - №2-1. - C. 270-271. doi: 10.31857/S102872210006597-1 | Zlatnik E.Yu., Bazaev A.L., Kochuev S.S. Prognostic significance of tissue cytokines` levels in some malignant tumors. Russian Journal of Immunology, 2019, Vol. 22, no.2-1, pp. 270-271. doi: 10.31857/S102872210006597-1 | <https://rusimmun.ru/jour/article/view/118/116> |
| 15 | Zlatnik E.Yu., Kochuev S.S., Demidova A.A., Przhedetzky Yu.V., Pozdniakova V.V., Khokhlova O.V., Novikova I.A. Prognosis of melanoma progression based on its cytokine microenvironment. J Clin Oncol, 2018, 36(15\_suppl), e21625. doi: 10.1200/JCO.2018.36.15\_suppl.e21625 | - | <https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.e21625> |